We are live on ! Find out more
Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Portfolio holdings

AUM $44.6B
1-Year Est. Return 28.94%
This Fund
S&P 500
This Quarter Est. Return
-0.75%
1 Year Est. Return
+28.94%
3 Year Est. Return
+82.62%
5 Year Est. Return
+90.41%
10 Year Est. Return
+293.66%
AUM
$20.3B
AUM Growth
-$658M
Cap. Flow
-$389M
Cap. Flow %
-1.92%
Top 10 Hldgs %
19.94%
Holding
3,276
New
193
Increased
1,504
Reduced
1,271
Closed
193

Sector Composition

Rank Sector Weight
1 Technology 9.58%
2 Consumer Discretionary 4.97%
3 Financials 4.87%
4 Healthcare 3.87%
5 Communication Services 3.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PSFE.WS
3051
DELISTED
Paysafe Ltd Warrants
PSFE.WS
$19K ﹤0.01%
+10,500
New +$25.5K
TTOO
3052
DELISTED
T2 Biosystems, Inc
TTOO
$18K ﹤0.01%
4
+1
+33% +$5.03K
CNSP icon
3053
CNS Pharmaceuticals
CNSP
$7.32M
0
XPL icon
3054
Solitario Resources
XPL
$73.6M
$17K ﹤0.01%
30,765
GORO icon
3055
Goldgroup Mining Inc.
GORO
$211M
$16K ﹤0.01%
10,386
-2,102
-17% -$3.99K
IBIO icon
3056
iBio
IBIO
$73M
$16K ﹤0.01%
+30
New +$18.7K
NBEV
3057
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$16K ﹤0.01%
11,290
-1,225
-10% -$2.23K
NAK
3058
Northern Dynasty Minerals
NAK
$953M
$15K ﹤0.01%
33,100
NGD
3059
DELISTED
New Gold Inc
NGD
$15K ﹤0.01%
14,319
TYME
3060
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$14K ﹤0.01%
14,000
THM
3061
International Tower Hill Mines
THM
$733M
$13K ﹤0.01%
17,775
-4,200
-19% -$3.77K
CRVO icon
3062
CervoMed
CRVO
$41.5M
$11K ﹤0.01%
277
TXMD icon
3063
TherapeuticsMD
TXMD
$24.1M
$11K ﹤0.01%
308
RGLS
3064
DELISTED
Regulus Therapeutics
RGLS
$10K ﹤0.01%
+1,400
New +$10.3K
TRX icon
3065
TRX Gold Corp
TRX
$360M
$10K ﹤0.01%
+20,000
New +$9.06K
NEPT
3066
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$10K ﹤0.01%
12
+3
+33% +$3.17K
GPL
3067
DELISTED
Great Panther Mining Limited
GPL
$10K ﹤0.01%
2,278
+850
+60% +$4.48K
PULM icon
3068
Pulmatrix
PULM
$5.84M
$8K ﹤0.01%
510
TALKW
3069
DELISTED
Talkspace Inc Warrant
TALKW
$8K ﹤0.01%
10,550
RMTI icon
3070
Rockwell Medical
RMTI
$29.6M
$7K ﹤0.01%
100
TBLT
3071
DELISTED
ToughBuilt Industries, Inc. Common Stock
TBLT
$5K ﹤0.01%
1
AHCO icon
3072
AdaptHealth
AHCO
$770M
-10,115
Closed -$277K
AIR icon
3073
AAR Corp
AIR
$5.96B
-7,153
Closed -$277K
AMZA icon
3074
InfraCap MLP ETF
AMZA
$478M
-8,769
Closed -$258K
ANF icon
3075
Abercrombie & Fitch
ANF
$4.99B
-6,035
Closed -$280K

Similar funds

Cambridge Investment Research Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Cambridge Investment Research Advisors held 3,276 positions worth $20.3B, down 3.1% from $20.9B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Cambridge Investment Research Advisors's Q3 2021 filing shows 193 new, 1,504 increased, 1,271 reduced and 193 closed positions. Its largest new stake was Dimensional World ex US Core Equity 2 ETF: 269,623 shares worth $6.98M. The largest sale was iShares S&P 500 Growth ETF, an estimated $90.8M.

By sector, the portfolio is most concentrated in Technology at 9.6% of assets, up from 9.3% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Cambridge Investment Research Advisors's largest Q3 2021 buy was Dimensional World ex US Core Equity 2 ETF: 269,623 shares worth $6.98M.
  • Cambridge Investment Research Advisors added most to iShares Core S&P US Growth ETF in Q3 2021, an estimated $42.5M increase.
  • Cambridge Investment Research Advisors's biggest Q3 2021 reduction was iShares S&P 500 Growth ETF, cutting an estimated $90.8M.
  • Cambridge Investment Research Advisors fully exited VanEck Steel ETF in Q3 2021, selling an estimated $6.22M.
  • Cambridge Investment Research Advisors's ten largest holdings make up 20% of its $20.3B portfolio in Q3 2021.
  • Cambridge Investment Research Advisors opened 193 new positions and closed 193 in Q3 2021.
  • Cambridge Investment Research Advisors's portfolio value fell 3.1% quarter-over-quarter to $20.3B.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.